天疱疮利妥昔单抗治疗后完全缓解的相关因素
这项单中心回顾性队列研究纳入112例天疱疮患者,评估利妥昔单抗治疗后完全缓解(CROT)率及预后因素。多因素分析显示,淋巴瘤剂量方案与较高年龄与CROT相关,而BMI≥35与CROT负相关。
要点
- 淋巴瘤剂量方案较类风湿关节炎方案更易达到CROT(OR 2.70)。
- 年龄增长与CROT率显著增加相关。
- BMI≥35是CROT的负性预后因素(OR 0.14)。
核心结论
- 淋巴瘤剂量方案和较高年龄可能与CROT相关,BMI≥35可能是CROT的负性预后因素。
研究设计与样本
- 单中心回顾性队列研究,纳入112例天疱疮患者,至少12个月临床随访。
- 患者来自宾夕法尼亚大学,接受利妥昔单抗治疗时间为2005年3月15日至2016年12月19日。
- 采用多因素回归分析CROT预测因素,Kaplan-Meier分析疾病复发。
主要发现
- 中位随访37.8个月(范围12.1-130.7),65例(58.0%)为女性,首次输注时中位年龄52.3岁(范围20.0-89.3)。
- 包括多疗程患者,79例(70.5%)达到CROT,中位时间10.5个月(范围2.0-49.8);72例中36例(50.0%)随后复发,中位时间23.3个月(IQR 10.8-50.4)。
- 仅考虑第一疗程,54例(48.2%)达到CROT。
临床怎么用
- 临床可参考淋巴瘤剂量方案和较高年龄预测CROT可能性,BMI≥35提示CROT可能性较低。
局限性
- 单中心回顾性研究设计可能引入选择偏倚。
- 研究结果需在前瞻性临床试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Rituximab has emerged as a front-line therapy for pemphigus, but prognostic factors for achieving complete remission off therapy (CROT) with oral systemic agents remain unknown. OBJECTIVES: To describe rates of CROT and relapse and identify prognostic factors for achieving CROT after rituximab therapy for pemphigus. DESIGN, SETTING, AND PARTICIPANTS: A single-center, retrospective, cohort study was conducted at the University of Pennsylvania including 112 patients with pemphigus treated with rituximab with at least 12 months' clinical follow-up after the start of rituximab therapy. Multivariate regression analysis of factors predictive of CROT and Kaplan-Meier analysis of disease relapse were conducted. The study included patients treated with rituximab from March 15, 2005, until December 19, 2016. Data analysis was performed from December 2017 to June 2018. MAIN OUTCOMES AND MEASURES: The primary study outcome was CROT after 1 cycle. Secondary study outcomes included rate of CROT or the composite end point of CROT or complete remission on minimal therapy after 1 or more cycle, and median time to relapse. Multivariate regression analysis for prognostic variables for CROT, including age, sex, pemphigus subtype, body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), disease duration, and dosing regimen, was performed. RESULTS: A total of 112 patients with pemphigus with median 37.8 months (range, 12.1-130.7) follow-up after rituximab therapy were identified. Of these, 65 were women (58.0%). At the time of first rituximab infusion, median age was 52.3 years (range, 20.0-89.3). Including patients who received multiple cycles of rituximab, 79 patients (70.5%) achieved CROT after a median time of 10.5 months (range, 2.0-49.8), and 36 of 72 patients (50.0%) subsequently experienced relapse after a median of 23.3 months (interquartile range, 10.8-50.4 months). Considering only the first cycle of rituximab, 54 patients (48.2%) achieved CROT. Controlling for age, sex, pemphigus subtype, BMI, and disease duration, patients who received lymphoma vs rheumatoid arthritis dosing were 2.70-fold more likely to achieve CROT (odds ratio [OR], 2.70; 95% CI, 1.03-7.12; P = .04). Increasing age was associated with significant increases in achieving CROT (Wald test for trend, P = .01), whereas BMI greater than or equal to 35 was associated with a 0.14 OR (95% CI, 0.03-0.63; P = .01) for achieving CROT, regardless of the dosing regimen. In multivariate analysis, there was no significant difference in CROT rates with sex (OR, 1.01; 95% CI, 0.42-2.50; P = .97), pemphigus subtype (OR, 0.37; 95% CI, 0.09-1.51; P = .17), or disease duration (OR, 0.99; 95% CI, 0.98-1.00; P = .09). CONCLUSIONS AND RELEVANCE: Lymphoma dosing and older age may be associated with CROT and BMI greater than or equal to 35 may be a negative prognostic factor for CROT after rituximab therapy for pemphigus. These findings help inform clinical expectations and merit evaluation in future prospective clinical trials.
引用
- Kushner CJ, Wang S, Tovanabutra N, et al. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. JAMA Dermatol. 2019. PMID: 31642878. doi:10.1001/jamadermatol.2019.3236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。